Summary
The provided AI claims primarily address foscarnet/cidofovir/brivudine/helicase-primase inhibitors and resistance management, which are not supported or addressed by the supplied FDA labeling excerpts for acyclovir oral suspension. Many statements include specific mechanisms, dosing, response rates, approval status, and administration routes for non-acyclovir products—none of which are supported by the provided label text.
Category Scores
Accurate Statements
Unsupported Statements
Acyclovir-resistant HSV or VZV strains can be treated with other antivirals that target different viral enzymes or mechanisms.
No information in the provided acyclovir oral suspension label excerpts addresses acyclovir resistance or selection of alternative antivirals.
Resistance to acyclovir in HSV or VZV typically arises from mutations in viral thymidine kinase (TK) or DNA polymerase, reducing acyclovir's phosphorylation or incorporation.
Mechanism/resistance information for HSV/VZV mutations is not present in the provided labeling excerpts.
Foscarnet is the primary option for acyclovir-resistant HSV.
The provided labeling excerpts are for acyclovir oral suspension only and contain no recommendations or prioritization involving foscarnet.
Foscarnet directly inhibits viral DNA polymerase without needing TK activation.
Mechanism statements about foscarnet are not supported by the provided acyclovir label excerpts.
Foscarnet is effective against TK-deficient HSV mutants.
No mutant/resistance-specific efficacy information involving foscarnet is in the provided acyclovir labeling excerpts.
Foscarnet is administered intravenously (e.g., 40–60 mg/kg every 8 hours).
The provided acyclovir label excerpts do not include foscarnet dosing/route.
Intravenous foscarnet achieves response rates over 80% in clinical studies for acyclovir-resistant HSV.
No response-rate data for foscarnet or acyclovir-resistant HSV is present in the provided acyclovir label excerpts.
Foscarnet nephrotoxicity requires monitoring.
Nephrotoxicity/monitoring information for foscarnet is not supported by the provided acyclovir oral suspension excerpts.
Cidofovir serves as a second-line choice for acyclovir-resistant HSV.
The provided acyclovir oral suspension labeling excerpts do not address cidofovir use or treatment line recommendations for resistant HSV.
Cidofovir bypasses TK via intracellular diphosphate conversion.
No mechanism information about cidofovir is included in the provided acyclovir label excerpts.
Cidofovir is used at 5 mg/kg weekly initially for acyclovir-resistant HSV.
No cidofovir dosing is present in the provided acyclovir oral suspension excerpts.
Cidofovir has similar efficacy to foscarnet in this setting.
No comparative efficacy data for cidofovir vs foscarnet in resistant HSV is present in the provided acyclovir label excerpts.
Cidofovir has higher renal risk.
No renal-risk comparative statements for cidofovir vs foscarnet are present in the provided acyclovir label excerpts.
Probenecid co-administration mitigates cidofovir-related renal risk.
While the provided excerpt mentions probenecid with intravenous acyclovir pharmacokinetics, it does not support cidofovir-specific renal risk mitigation.
For acyclovir-resistant VZV (e.g., in shingles), foscarnet remains first-line.
No label support for acyclovir-resistant VZV treatment prioritization involving foscarnet.
Brivudine is an oral alternative for acyclovir-resistant VZV in some regions.
No brivudine information is present in the provided acyclovir oral suspension excerpts.
Brivudine is not FDA-approved in the US.
Regulatory approval status of brivudine is not addressed in the provided acyclovir oral suspension excerpts.
Imiquimod cream provides topical relief for cutaneous lesions in VZV.
No imiquimod/VZV topical management statements are present in the provided acyclovir label excerpts.
Imiquimod cream does not eradicate systemic virus.
No imiquimod information is present in the provided acyclovir oral suspension excerpts.
Valacyclovir and famciclovir are prodrugs that convert to acyclovir and penciclovir, respectively.
Prodrug/conversion details for valacyclovir/famciclovir are not present in the provided acyclovir oral suspension excerpts.
Cross-resistance is common in TK-mutant strains for valacyclovir and famciclovir.
No resistance/cross-resistance information for valacyclovir or famciclovir is present in the provided acyclovir label excerpts.
Valacyclovir and famciclovir fail where acyclovir does.
No comparative failure/success claims for other antivirals vs acyclovir are in the provided acyclovir label excerpts.
Investigational helicase-primase inhibitors like pritelivir show promise against resistant HSV.
No information about pritelivir or investigational antivirals is present in the provided acyclovir label excerpts.
Pritelivir inhibits HSV replication upstream of polymerase.
No mechanism information about pritelivir is present in the provided acyclovir label excerpts.
Phase 2 trials of pritelivir for acyclovir failures report viral load reductions.
No pritelivir trial outcomes are present in the provided acyclovir label excerpts.
Pritelivir is not yet approved.
Approval status of pritelivir is not addressed in the provided acyclovir oral suspension excerpts.
Combining foscarnet with antivirals like letermovir is explored in refractory cases.
No combination therapy or letermovir information is present in the provided acyclovir label excerpts.
Foscarnet and cidofovir carry renal toxicity.
Renal toxicity statements for foscarnet/cidofovir are not supported by the provided acyclovir oral suspension label excerpts.
The incidence of renal toxicity with foscarnet and cidofovir is reported as up to 30%.
No incidence figures for foscarnet/cidofovir renal toxicity are present in the provided acyclovir label excerpts.
Foscarnet and cidofovir can cause electrolyte imbalances.
No electrolyte-imbalance statements for foscarnet/cidofovir are present in the provided acyclovir label excerpts.
Foscarnet and cidofovir require intravenous administration.
No route information for foscarnet/cidofovir is present in the provided acyclovir oral suspension excerpts.
Resistance testing via genotypic assays guides therapy.
No resistance-testing/assay-guided therapy information is present in the provided acyclovir label excerpts.
Phenotypic testing confirms susceptibility.
No phenotypic testing information is present in the provided acyclovir label excerpts.
Mortality from resistant HSV encephalitis can exceed 50% without prompt switching.
No mortality/statistics for resistant HSV encephalitis are present in the provided acyclovir oral suspension label excerpts.
Contradictions
Important Omissions
If the intended drug was acyclovir oral suspension, the response omits FDA-labeled indications and dosing for acyclovir (e.g., herpes zoster 800 mg five times daily; genital herpes and chickenpox dosing; renal impairment dose modifications).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The claims introduce multiple non-acyclovir therapies and highly specific dosing/efficacy/approval/status statements that are not supported by the supplied FDA label excerpts for acyclovir oral suspension, increasing the likelihood of misinformation and inappropriate treatment decisions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are not supported by the provided FDA-approved acyclovir oral suspension prescribing information excerpts and concern other drugs (foscarnet, cidofovir, brivudine, pritelivir, letermovir, imiquimod) not covered in the provided label text.
Suggested Improvement
Limit claims strictly to FDA-labeled acyclovir oral suspension information from the provided excerpts (indications, dosing/administration, contraindications, warnings, adverse reactions, and labeled precautions such as renal/CNS adverse events). Remove or qualify statements about resistance management and non-acyclovir agents unless the corresponding FDA label excerpts for those specific drugs are provided.